Convergent results obtained by Opitz and colleagues revealed that tumors expressing TDO degrade tryptophan in kynurenine, which suppresses an anti-tumor immune response through the AHR axis (Opitz et al., 2011). The gene discussed is TDO2; the disease is neoplasm.